Here is a roundup of the latest research on Menoapuse.
In this
article:
Early
menopause ups the risk of developing type 2 diabetes
Women who
have an early natural menopause have 2.5 times the risk of developing type 2
diabetes as compared to women who have normal menopause reports the results of
a large population based study published online July 18, 2017 in Journal
Diabetologia.
Oophorectomy
during premenopausal hysterectomy: Evaluating the prevalence
Nearly 1 in
3 women undergo oophorectomy during premenopausal hysterectomy in absence of
appropriate indication, reports a study published ahead of print May 8, 2017 in
North American Menopausal Society (NAMS) journal Menopause.
Loss of
estrogen in postmenopausal women puts them at high risk for lumbar disc
degeneration.
Declining
estrogen levels during perimenopausal and menopausal years is associated with
severe lumbar disc degeneration reports a study published online June 12, 2017
in journal Menopause, the journal of The North American Menopause Society
(NAMS).
ACP updates
guideline for treating Osteoporosis.
According to
International Osteoporotic Foundation (IOF), 1 in 3 women over age 50 will
experience osteoporotic fractures and nearly 200 million women suffer from
osteoporosis worldwide.
Polycystic
ovarian syndrome increases the risk of subsequent early ovarian aging later in
life.
Women with
polycystic ovarian syndrome (PCOS) have 8.64-fold increase in risk of
developing premature ovarian failure as compared to women who did not have PCOS
according to a population based study in forthcoming issue of Journal
Menopause. Metformin was found to be effective in reducing such risk.
New natural
(bioidentical) 17ß-estradiol-progesterone combination available as single soft
gel capsules effective in treating postmenopausal symptoms: News from ENDO17
An
innovative, investigational combination of 17ß-estradiol and progesterone in a
single, oral softgel, was found effective for the treatment of moderate to
severe vasomotor symptoms (VMS) due to menopause. The results of the study were
presented at the ENDO 2017, the annual meeting of the Endocrine Society in
Orlando, Florida, April 1-4.
New class of
drug effective in targeting menopausal symptoms: News from Endocrine Conference
2017.
A new class
of drug Neurokinin 3 (NK3) receptor antagonists is highly effective and low
risk alternative to hormone replacement therapy(HRT) for treatment of
menopausal hot flashes according to a study presented at the ENDO 2017, The
endocrine society annual meeting from April 1–4, 2017, in Orlando, FL.
Menarche ≤11
years and Nulliparity is a risk factor for Premature and Early Menopause.
Women who
had their first period at or before the age of 11 are at increased risk for
premature and early menopause and the risk is further amplified if the woman is
nulliparous according to a large observational study published on January 25,
2017 in Oxford Journal of Human Reproduction.
